Last reviewed · How we verify
A Phase I Open-label Study of the Safety and Immunogenicity of Escalating Doses of Lipovaxin-MM, a Novel Melanoma Immunotherapeutic, in Patients With Metastatic Melanoma
The purpose of this study is to determine whether Lipovaxin-MM, a new anti-cancer vaccine, is safe and effective in improving the body's ability to destroy cancer cells in patients with metastatic melanoma.
Details
| Lead sponsor | Lipotek Pty Ltd |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 12 |
| Start date | 2009-09 |
| Completion | 2012-03 |
Conditions
- Melanoma
Interventions
- Lipovaxin-MM
Primary outcomes
- Adverse events — Within 84 days after first dose
- Immunogenicity — Within 42 days of first dose
antigen specific immune responses will be monitored
Countries
Australia